• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infection . Epidemiology of SARS-CoV-2

tetano

Editor, Senior Moderator
Infection


. 2020 Oct 8.
doi: 10.1007/s15010-020-01531-3. Online ahead of print.
Epidemiology of SARS-CoV-2


Bernd Salzberger[SUP] 1 [/SUP], Felix Buder[SUP] 2 [/SUP], Benedikt Lampl[SUP] 3 [/SUP], Boris Ehrenstein[SUP] 4 [/SUP], Florian Hitzenbichler[SUP] 2 [/SUP], Thomas Holzmann[SUP] 2 [/SUP], Barbara Schmidt[SUP] 5 [/SUP], Frank Hanses[SUP] 2 [/SUP]



Affiliations

Abstract

Purpose: SARS-CoV-2 is a recently emerged ?-coronavirus. Here we present the current knowledge on its epidemiologic features.
Methods: Non-systematic review.
Results: SARS-CoV-2 replicates in the upper and lower respiratory tract. It is mainly transmitted by droplets and aerosols from asymptomatic and symptomatic infected subjects. The consensus estimate for the basis reproduction number (R[SUB]0[/SUB]) is between 2 and 3, and the median incubation period is 5.7 (range 2-14) days. Similar to SARS and MERS, superspreading events have been reported, the dispersion parameter (kappa) is estimated at 0.1. Most infections are uncomplicated, and 5-10% of patients are hospitalized, mainly due to pneumonia with severe inflammation. Complications are respiratory and multiorgan failure; risk factors for complicated disease are higher age, hypertension, diabetes, chronic cardiovascular, chronic pulmonary disease and immunodeficiency. Nosocomial and infections in medical personnel have been reported. Drastic reductions of social contacts have been implemented in many countries with outbreaks of SARS-CoV-2, leading to rapid reductions. Most interventions have used bundles, but which of the measures have been more or less effective is still unknown. The current estimate for the infection's fatality rate is 0.5-1%. Using current models of age-dependent infection fatality rates, upper and lower limits for the attack rate in Germany can be estimated between 0.4 and 1.6%, lower than in most European countries.
Conclusions: Despite a rapid worldwide spread, attack rates have been low in most regions, demonstrating the efficacy of control measures.

Keywords: Basic reproduction number; COVID-19; Epidemiology; Incubation period; Infection fatality risk; Mortality; Pandemic; SARS-CoV-2.
 
Back
Top Bottom